Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Fraction unbound in plasma of human CGRPalpha-induced migraine marmoset model at 7 mg/kg, sc measured after 15 to 105 mins
Assay data:3 Tested
SummaryPubMed Citation
Total plasma concentration in human CGRPalpha-induced migraine marmoset model at 3 mg/kg, sc measured after 15 to 105 mins
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed Citation
Total plasma concentration in human CGRPalpha-induced migraine marmoset model at 7 mg/kg, sc measured after 15 to 105 mins
Assay data:3 Active, 3 Activity ≤ 1 µM, 3 Tested
Antimigraine activity in human CGRPalpha-induced migraine marmoset model assessed as reduction in facial blood flow at 7 mg/kg, sc administered 30 mins after CGRPalpha stimulation measured after 15 to 105 mins by laser doppler method relative to control
Assay data:1 Tested
Antimigraine activity in human CGRPalpha-induced migraine marmoset model assessed as reduction in facial blood flow at 3 mg/kg, sc administered 30 mins after CGRPalpha stimulation measured after 15 to 105 mins by laser doppler method relative to control
Antimigraine activity in human CGRPalpha-induced migraine marmoset model assessed as reduction in facial blood flow at 7 mg/kg, sc administered 30 mins after CGRPalpha stimulation measured after 105 mins by laser doppler method relative to control
Antimigraine activity in human CGRPalpha-induced migraine marmoset model assessed as reduction in facial blood flow at 7 mg/kg, sc administered 30 mins after CGRPalpha stimulation measured after 60 mins by laser doppler method relative to control
Antimigraine activity in human CGRPalpha-induced migraine marmoset model assessed as reduction in facial blood flow at 7 mg/kg, sc administered 30 mins after CGRPalpha stimulation measured after 15 mins by laser doppler method relative to control
Agonist activity at marmoset beta3-adrenergic receptor
Cmax (0-168h) of total radioactivity following single intravenous administration of [14C] aliskiren hemifumarate at 1 mg.Kg-1 level in marmoset
Summary
Cmax (0-168h) of unlabeled aliskiren hemifumarate following single intravenous administration of aliskiren hemifumarate at 1 mg.Kg-1 level in marmoset
Cmax (0-168h) of total radioactivity following single oral administration of [14C] aliskiren hemifumarate at 3 mg.Kg-1 level in marmoset
SummaryCompounds, ActiveCompounds, activity ≤ 1 µM
Cmax (0-168h) of unlabeled aliskiren hemifumarate following single oral administration of aliskiren hemifumarate at 3 mg.Kg-1 level in marmoset
Displacement of [3H]GR205171 from marmoset cerebral striatum NK1 receptor after 60 mins by scintillation counting analysis
Assay data:1 Active, 1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 1 Tested
Plasma concentration in marmoset at 0.03 mg/kg, sc measured 15 to 105 mins post-dose
Plasma concentration in marmoset at 0.03 g/kg, sc after 15 mins
Plasma concentration in marmoset at 0.03 g/kg, sc after 105 mins
Plasma concentration in marmoset at 0.03 g/kg, sc after 60 mins
Plasma concentration in Harlan marmoset at 7 mg/kg, sc at 15 mins
Plasma concentration in Harlan marmoset at 7 mg/kg, sc after 60 to 105 mins
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on